Lund, Sweden

Laura Von Schantz

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 7.9

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Laura von Schantz: Innovator in Bispecific Polypeptides

Introduction

Laura von Schantz is a prominent inventor based in Lund, Sweden. She has made significant contributions to the field of biomedicine, particularly through her innovative work on bispecific polypeptides. Her dedication to research and development in this area has led to the filing of a patent that enhances therapeutic options for cancer treatments.

Latest Patents

Laura's most notable patent is focused on bispecific polypeptides against CD137. This invention comprises bispecific polypeptides featuring a first binding domain, designated B1, which specifically binds to CD137, and a second binding domain, designated B2, that targets a tumour cell-associated antigen. The patent also encompasses pharmaceutical compositions of these bispecific polypeptides and their medical applications, representing a promising avenue for future therapies.

Career Highlights

Laura von Schantz is currently affiliated with Alligator Bioscience AB. Her role within this innovative company underscores her commitment to advancing cancer therapies through the development of novel pharmaceutical products. The work she has contributed to exemplifies the intersection of biotechnology and therapeutic advancement.

Collaborations

Throughout her career, Laura has collaborated with esteemed colleagues, including Eva Dahlén and Peter Ellmark. Their efforts collectively contribute to the advancement of innovative biomedical solutions, fostering an environment of collaboration that drives research forward.

Conclusion

In conclusion, Laura von Schantz stands out as a key figure in the realm of innovative medicine. Her patent on bispecific polypeptides is a testament to her ingenuity and commitment to improving patient outcomes. With her ongoing efforts at Alligator Bioscience AB and her collaborative partnerships, Laura continues to pave the way for advancements in cancer therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…